Industry Research Reports

Home > Reports > Medical Care > Sickle-cell Anemia Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Sickle-cell Anemia Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-01-24

Pages: 104 Pages

Report ld: 2343975

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

The global market for Sickle-cell Anemia Therapeutics was estimated to be worth US$ 1845.9 million in 2023 and is forecast to a readjusted size of US$ 5067.2 million by 2030 with a CAGR of 15.0% during the forecast period 2024-2030

Sickle-cell Anemia Therapeutics Market Size

M= millions and B=billions

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Sickle-cell Anemia Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Sickle-cell Anemia Therapeutics by region & country, by Type, and by User.

The Sickle-cell Anemia Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sickle-cell Anemia Therapeutics.

Market Segmentation

Report Metric
Details
Report Title
Sickle-cell Anemia Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Forecasted Market Size in 2030
US$ 5067.2 million
CAGR(2024-2030)
15%
Market Size Available for Years
2019-2030
Global Sickle-cell Anemia Therapeutics Companies Covered
Addmedica, Gamida Cell, GlycoMimetics, Pfizer, Novartis, Global Blood Therapeutics, Micelle BioPharma, Bluebird Bio, Prolong Pharmaceuticals, Modus Therapeutics, Sangamo Biosciences, Bioverativ, Imara, Ironwood Pharmaceuticals
Global Sickle-cell Anemia Therapeutics Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Sickle-cell Anemia Therapeutics Market, Segment by Type
Blood Transfusion

Pharmacotherapy

Bone Marrow Transplant
Global Sickle-cell Anemia Therapeutics Market, Segment by Application
Child

Adult
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Sickle-cell Anemia Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by User, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Sickle-cell Anemia Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Sickle-cell Anemia Therapeutics in country level. It provides sigmate data by Type, and by User for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Sickle-cell Anemia Therapeutics Product Introduction
    1.2 Global Sickle-cell Anemia Therapeutics Market Size Forecast
    1.3 Sickle-cell Anemia Therapeutics Market Trends & Drivers
        1.3.1 Sickle-cell Anemia Therapeutics Industry Trends
        1.3.2 Sickle-cell Anemia Therapeutics Market Drivers & Opportunity
        1.3.3 Sickle-cell Anemia Therapeutics Market Challenges
        1.3.4 Sickle-cell Anemia Therapeutics Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Sickle-cell Anemia Therapeutics Players Revenue Ranking (2023)
    2.2 Global Sickle-cell Anemia Therapeutics Revenue by Company (2019-2024)
    2.3 Key Companies Sickle-cell Anemia Therapeutics Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Sickle-cell Anemia Therapeutics Product Offered
    2.5 Key Companies Time to Begin Mass Production of Sickle-cell Anemia Therapeutics
    2.6 Sickle-cell Anemia Therapeutics Market Competitive Analysis
        2.6.1 Sickle-cell Anemia Therapeutics Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Sickle-cell Anemia Therapeutics Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sickle-cell Anemia Therapeutics as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Blood Transfusion
        3.1.2 Pharmacotherapy
        3.1.3 Bone Marrow Transplant
    3.2 Global Sickle-cell Anemia Therapeutics Sales Value by Type
        3.2.1 Global Sickle-cell Anemia Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Sickle-cell Anemia Therapeutics Sales Value, by Type (2019-2030)
        3.2.3 Global Sickle-cell Anemia Therapeutics Sales Value, by Type (%) (2019-2030)

 4 Segmentation by User
    4.1 Introduction by User
        4.1.1 Child
        4.1.2 Adult
    4.2 Global Sickle-cell Anemia Therapeutics Sales Value by User
        4.2.1 Global Sickle-cell Anemia Therapeutics Sales Value by User (2019 VS 2023 VS 2030)
        4.2.2 Global Sickle-cell Anemia Therapeutics Sales Value, by User (2019-2030)
        4.2.3 Global Sickle-cell Anemia Therapeutics Sales Value, by User (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Sickle-cell Anemia Therapeutics Sales Value by Region
        5.1.1 Global Sickle-cell Anemia Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Sickle-cell Anemia Therapeutics Sales Value by Region (2019-2024)
        5.1.3 Global Sickle-cell Anemia Therapeutics Sales Value by Region (2025-2030)
        5.1.4 Global Sickle-cell Anemia Therapeutics Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Sickle-cell Anemia Therapeutics Sales Value, 2019-2030
        5.2.2 North America Sickle-cell Anemia Therapeutics Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Sickle-cell Anemia Therapeutics Sales Value, 2019-2030
        5.3.2 Europe Sickle-cell Anemia Therapeutics Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Sickle-cell Anemia Therapeutics Sales Value, 2019-2030
        5.4.2 Asia Pacific Sickle-cell Anemia Therapeutics Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Sickle-cell Anemia Therapeutics Sales Value, 2019-2030
        5.5.2 South America Sickle-cell Anemia Therapeutics Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Sickle-cell Anemia Therapeutics Sales Value, 2019-2030
        5.6.2 Middle East & Africa Sickle-cell Anemia Therapeutics Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Sickle-cell Anemia Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Sickle-cell Anemia Therapeutics Sales Value
    6.3 United States
        6.3.1 United States Sickle-cell Anemia Therapeutics Sales Value, 2019-2030
        6.3.2 United States Sickle-cell Anemia Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Sickle-cell Anemia Therapeutics Sales Value by User, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Sickle-cell Anemia Therapeutics Sales Value, 2019-2030
        6.4.2 Europe Sickle-cell Anemia Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Sickle-cell Anemia Therapeutics Sales Value by User, 2023 VS 2030
    6.5 China
        6.5.1 China Sickle-cell Anemia Therapeutics Sales Value, 2019-2030
        6.5.2 China Sickle-cell Anemia Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Sickle-cell Anemia Therapeutics Sales Value by User, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Sickle-cell Anemia Therapeutics Sales Value, 2019-2030
        6.6.2 Japan Sickle-cell Anemia Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Sickle-cell Anemia Therapeutics Sales Value by User, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Sickle-cell Anemia Therapeutics Sales Value, 2019-2030
        6.7.2 South Korea Sickle-cell Anemia Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Sickle-cell Anemia Therapeutics Sales Value by User, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Sickle-cell Anemia Therapeutics Sales Value, 2019-2030
        6.8.2 Southeast Asia Sickle-cell Anemia Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Sickle-cell Anemia Therapeutics Sales Value by User, 2023 VS 2030
    6.9 India
        6.9.1 India Sickle-cell Anemia Therapeutics Sales Value, 2019-2030
        6.9.2 India Sickle-cell Anemia Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Sickle-cell Anemia Therapeutics Sales Value by User, 2023 VS 2030

 7 Company Profiles
    7.1 Addmedica
        7.1.1 Addmedica Profile
        7.1.2 Addmedica Main Business
        7.1.3 Addmedica Sickle-cell Anemia Therapeutics Products, Services and Solutions
        7.1.4 Addmedica Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2019-2024)
        7.1.5 Addmedica Recent Developments
    7.2 Gamida Cell
        7.2.1 Gamida Cell Profile
        7.2.2 Gamida Cell Main Business
        7.2.3 Gamida Cell Sickle-cell Anemia Therapeutics Products, Services and Solutions
        7.2.4 Gamida Cell Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2019-2024)
        7.2.5 Gamida Cell Recent Developments
    7.3 GlycoMimetics
        7.3.1 GlycoMimetics Profile
        7.3.2 GlycoMimetics Main Business
        7.3.3 GlycoMimetics Sickle-cell Anemia Therapeutics Products, Services and Solutions
        7.3.4 GlycoMimetics Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2019-2024)
        7.3.5 Pfizer Recent Developments
    7.4 Pfizer
        7.4.1 Pfizer Profile
        7.4.2 Pfizer Main Business
        7.4.3 Pfizer Sickle-cell Anemia Therapeutics Products, Services and Solutions
        7.4.4 Pfizer Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2019-2024)
        7.4.5 Pfizer Recent Developments
    7.5 Novartis
        7.5.1 Novartis Profile
        7.5.2 Novartis Main Business
        7.5.3 Novartis Sickle-cell Anemia Therapeutics Products, Services and Solutions
        7.5.4 Novartis Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2019-2024)
        7.5.5 Novartis Recent Developments
    7.6 Global Blood Therapeutics
        7.6.1 Global Blood Therapeutics Profile
        7.6.2 Global Blood Therapeutics Main Business
        7.6.3 Global Blood Therapeutics Sickle-cell Anemia Therapeutics Products, Services and Solutions
        7.6.4 Global Blood Therapeutics Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2019-2024)
        7.6.5 Global Blood Therapeutics Recent Developments
    7.7 Micelle BioPharma
        7.7.1 Micelle BioPharma Profile
        7.7.2 Micelle BioPharma Main Business
        7.7.3 Micelle BioPharma Sickle-cell Anemia Therapeutics Products, Services and Solutions
        7.7.4 Micelle BioPharma Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2019-2024)
        7.7.5 Micelle BioPharma Recent Developments
    7.8 Bluebird Bio
        7.8.1 Bluebird Bio Profile
        7.8.2 Bluebird Bio Main Business
        7.8.3 Bluebird Bio Sickle-cell Anemia Therapeutics Products, Services and Solutions
        7.8.4 Bluebird Bio Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2019-2024)
        7.8.5 Bluebird Bio Recent Developments
    7.9 Prolong Pharmaceuticals
        7.9.1 Prolong Pharmaceuticals Profile
        7.9.2 Prolong Pharmaceuticals Main Business
        7.9.3 Prolong Pharmaceuticals Sickle-cell Anemia Therapeutics Products, Services and Solutions
        7.9.4 Prolong Pharmaceuticals Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2019-2024)
        7.9.5 Prolong Pharmaceuticals Recent Developments
    7.10 Modus Therapeutics
        7.10.1 Modus Therapeutics Profile
        7.10.2 Modus Therapeutics Main Business
        7.10.3 Modus Therapeutics Sickle-cell Anemia Therapeutics Products, Services and Solutions
        7.10.4 Modus Therapeutics Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2019-2024)
        7.10.5 Modus Therapeutics Recent Developments
    7.11 Sangamo Biosciences
        7.11.1 Sangamo Biosciences Profile
        7.11.2 Sangamo Biosciences Main Business
        7.11.3 Sangamo Biosciences Sickle-cell Anemia Therapeutics Products, Services and Solutions
        7.11.4 Sangamo Biosciences Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2019-2024)
        7.11.5 Sangamo Biosciences Recent Developments
    7.12 Bioverativ
        7.12.1 Bioverativ Profile
        7.12.2 Bioverativ Main Business
        7.12.3 Bioverativ Sickle-cell Anemia Therapeutics Products, Services and Solutions
        7.12.4 Bioverativ Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2019-2024)
        7.12.5 Bioverativ Recent Developments
    7.13 Imara
        7.13.1 Imara Profile
        7.13.2 Imara Main Business
        7.13.3 Imara Sickle-cell Anemia Therapeutics Products, Services and Solutions
        7.13.4 Imara Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2019-2024)
        7.13.5 Imara Recent Developments
    7.14 Ironwood Pharmaceuticals
        7.14.1 Ironwood Pharmaceuticals Profile
        7.14.2 Ironwood Pharmaceuticals Main Business
        7.14.3 Ironwood Pharmaceuticals Sickle-cell Anemia Therapeutics Products, Services and Solutions
        7.14.4 Ironwood Pharmaceuticals Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2019-2024)
        7.14.5 Ironwood Pharmaceuticals Recent Developments

 8 Industry Chain Analysis
    8.1 Sickle-cell Anemia Therapeutics Industrial Chain
    8.2 Sickle-cell Anemia Therapeutics Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Sickle-cell Anemia Therapeutics Sales Model
        8.5.2 Sales Channel
        8.5.3 Sickle-cell Anemia Therapeutics Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Sickle-cell Anemia Therapeutics Market Trends
    Table 2. Sickle-cell Anemia Therapeutics Market Drivers & Opportunity
    Table 3. Sickle-cell Anemia Therapeutics Market Challenges
    Table 4. Sickle-cell Anemia Therapeutics Market Restraints
    Table 5. Global Sickle-cell Anemia Therapeutics Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Sickle-cell Anemia Therapeutics Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Sickle-cell Anemia Therapeutics Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Sickle-cell Anemia Therapeutics Product Type
    Table 9. Key Companies Time to Begin Mass Production of Sickle-cell Anemia Therapeutics
    Table 10. Global Sickle-cell Anemia Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sickle-cell Anemia Therapeutics as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Sickle-cell Anemia Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Sickle-cell Anemia Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Sickle-cell Anemia Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Sickle-cell Anemia Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Sickle-cell Anemia Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Sickle-cell Anemia Therapeutics Sales Value by User: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Sickle-cell Anemia Therapeutics Sales Value by User (2019-2024) & (US$ Million)
    Table 20. Global Sickle-cell Anemia Therapeutics Sales Value by User (2025-2030) & (US$ Million)
    Table 21. Global Sickle-cell Anemia Therapeutics Sales Market Share in Value by User (2019-2024) & (%)
    Table 22. Global Sickle-cell Anemia Therapeutics Sales Market Share in Value by User (2025-2030) & (%)
    Table 23. Global Sickle-cell Anemia Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Sickle-cell Anemia Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Sickle-cell Anemia Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Sickle-cell Anemia Therapeutics Sales Value by Region (2019-2024) & (%)
    Table 27. Global Sickle-cell Anemia Therapeutics Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Sickle-cell Anemia Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Sickle-cell Anemia Therapeutics Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Sickle-cell Anemia Therapeutics Sales Value, (2025-2030) & (US$ Million)
    Table 31. Addmedica Basic Information List
    Table 32. Addmedica Description and Business Overview
    Table 33. Addmedica Sickle-cell Anemia Therapeutics Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Sickle-cell Anemia Therapeutics Business of Addmedica (2019-2024)
    Table 35. Addmedica Recent Developments
    Table 36. Gamida Cell Basic Information List
    Table 37. Gamida Cell Description and Business Overview
    Table 38. Gamida Cell Sickle-cell Anemia Therapeutics Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Sickle-cell Anemia Therapeutics Business of Gamida Cell (2019-2024)
    Table 40. Gamida Cell Recent Developments
    Table 41. GlycoMimetics Basic Information List
    Table 42. GlycoMimetics Description and Business Overview
    Table 43. GlycoMimetics Sickle-cell Anemia Therapeutics Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Sickle-cell Anemia Therapeutics Business of GlycoMimetics (2019-2024)
    Table 45. GlycoMimetics Recent Developments
    Table 46. Pfizer Basic Information List
    Table 47. Pfizer Description and Business Overview
    Table 48. Pfizer Sickle-cell Anemia Therapeutics Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Sickle-cell Anemia Therapeutics Business of Pfizer (2019-2024)
    Table 50. Pfizer Recent Developments
    Table 51. Novartis Basic Information List
    Table 52. Novartis Description and Business Overview
    Table 53. Novartis Sickle-cell Anemia Therapeutics Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Sickle-cell Anemia Therapeutics Business of Novartis (2019-2024)
    Table 55. Novartis Recent Developments
    Table 56. Global Blood Therapeutics Basic Information List
    Table 57. Global Blood Therapeutics Description and Business Overview
    Table 58. Global Blood Therapeutics Sickle-cell Anemia Therapeutics Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Sickle-cell Anemia Therapeutics Business of Global Blood Therapeutics (2019-2024)
    Table 60. Global Blood Therapeutics Recent Developments
    Table 61. Micelle BioPharma Basic Information List
    Table 62. Micelle BioPharma Description and Business Overview
    Table 63. Micelle BioPharma Sickle-cell Anemia Therapeutics Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Sickle-cell Anemia Therapeutics Business of Micelle BioPharma (2019-2024)
    Table 65. Micelle BioPharma Recent Developments
    Table 66. Bluebird Bio Basic Information List
    Table 67. Bluebird Bio Description and Business Overview
    Table 68. Bluebird Bio Sickle-cell Anemia Therapeutics Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Sickle-cell Anemia Therapeutics Business of Bluebird Bio (2019-2024)
    Table 70. Bluebird Bio Recent Developments
    Table 71. Prolong Pharmaceuticals Basic Information List
    Table 72. Prolong Pharmaceuticals Description and Business Overview
    Table 73. Prolong Pharmaceuticals Sickle-cell Anemia Therapeutics Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Sickle-cell Anemia Therapeutics Business of Prolong Pharmaceuticals (2019-2024)
    Table 75. Prolong Pharmaceuticals Recent Developments
    Table 76. Modus Therapeutics Basic Information List
    Table 77. Modus Therapeutics Description and Business Overview
    Table 78. Modus Therapeutics Sickle-cell Anemia Therapeutics Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Sickle-cell Anemia Therapeutics Business of Modus Therapeutics (2019-2024)
    Table 80. Modus Therapeutics Recent Developments
    Table 81. Sangamo Biosciences Basic Information List
    Table 82. Sangamo Biosciences Description and Business Overview
    Table 83. Sangamo Biosciences Sickle-cell Anemia Therapeutics Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Sickle-cell Anemia Therapeutics Business of Sangamo Biosciences (2019-2024)
    Table 85. Sangamo Biosciences Recent Developments
    Table 86. Bioverativ Basic Information List
    Table 87. Bioverativ Description and Business Overview
    Table 88. Bioverativ Sickle-cell Anemia Therapeutics Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Sickle-cell Anemia Therapeutics Business of Bioverativ (2019-2024)
    Table 90. Bioverativ Recent Developments
    Table 91. Imara Basic Information List
    Table 92. Imara Description and Business Overview
    Table 93. Imara Sickle-cell Anemia Therapeutics Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Sickle-cell Anemia Therapeutics Business of Imara (2019-2024)
    Table 95. Imara Recent Developments
    Table 96. Ironwood Pharmaceuticals Basic Information List
    Table 97. Ironwood Pharmaceuticals Description and Business Overview
    Table 98. Ironwood Pharmaceuticals Sickle-cell Anemia Therapeutics Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Sickle-cell Anemia Therapeutics Business of Ironwood Pharmaceuticals (2019-2024)
    Table 100. Ironwood Pharmaceuticals Recent Developments
    Table 101. Key Raw Materials Lists
    Table 102. Raw Materials Key Suppliers Lists
    Table 103. Sickle-cell Anemia Therapeutics Downstream Customers
    Table 104. Sickle-cell Anemia Therapeutics Distributors List
    Table 105. Research Programs/Design for This Report
    Table 106. Key Data Information from Secondary Sources
    Table 107. Key Data Information from Primary Sources
    Table 108. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Sickle-cell Anemia Therapeutics Product Picture
    Figure 2. Global Sickle-cell Anemia Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Sickle-cell Anemia Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 4. Sickle-cell Anemia Therapeutics Report Years Considered
    Figure 5. Global Sickle-cell Anemia Therapeutics Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Sickle-cell Anemia Therapeutics Revenue in 2023
    Figure 7. Sickle-cell Anemia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Blood Transfusion Picture
    Figure 9. Pharmacotherapy Picture
    Figure 10. Bone Marrow Transplant Picture
    Figure 11. Global Sickle-cell Anemia Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 12. Global Sickle-cell Anemia Therapeutics Sales Value Market Share by Type, 2023 & 2030
    Figure 13. Product Picture of Child
    Figure 14. Product Picture of Adult
    Figure 15. Global Sickle-cell Anemia Therapeutics Sales Value by User (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 16. Global Sickle-cell Anemia Therapeutics Sales Value Market Share by User, 2023 & 2030
    Figure 17. North America Sickle-cell Anemia Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 18. North America Sickle-cell Anemia Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 19. Europe Sickle-cell Anemia Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 20. Europe Sickle-cell Anemia Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 21. Asia Pacific Sickle-cell Anemia Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 22. Asia Pacific Sickle-cell Anemia Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 23. South America Sickle-cell Anemia Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 24. South America Sickle-cell Anemia Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 25. Middle East & Africa Sickle-cell Anemia Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 26. Middle East & Africa Sickle-cell Anemia Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 27. Key Countries/Regions Sickle-cell Anemia Therapeutics Sales Value (%), (2019-2030)
    Figure 28. United States Sickle-cell Anemia Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 29. United States Sickle-cell Anemia Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 30. United States Sickle-cell Anemia Therapeutics Sales Value by User (%), 2023 VS 2030
    Figure 31. Europe Sickle-cell Anemia Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 32. Europe Sickle-cell Anemia Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 33. Europe Sickle-cell Anemia Therapeutics Sales Value by User (%), 2023 VS 2030
    Figure 34. China Sickle-cell Anemia Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 35. China Sickle-cell Anemia Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 36. China Sickle-cell Anemia Therapeutics Sales Value by User (%), 2023 VS 2030
    Figure 37. Japan Sickle-cell Anemia Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 38. Japan Sickle-cell Anemia Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 39. Japan Sickle-cell Anemia Therapeutics Sales Value by User (%), 2023 VS 2030
    Figure 40. South Korea Sickle-cell Anemia Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 41. South Korea Sickle-cell Anemia Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 42. South Korea Sickle-cell Anemia Therapeutics Sales Value by User (%), 2023 VS 2030
    Figure 43. Southeast Asia Sickle-cell Anemia Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 44. Southeast Asia Sickle-cell Anemia Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 45. Southeast Asia Sickle-cell Anemia Therapeutics Sales Value by User (%), 2023 VS 2030
    Figure 46. India Sickle-cell Anemia Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 47. India Sickle-cell Anemia Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 48. India Sickle-cell Anemia Therapeutics Sales Value by User (%), 2023 VS 2030
    Figure 49. Sickle-cell Anemia Therapeutics Industrial Chain
    Figure 50. Sickle-cell Anemia Therapeutics Manufacturing Cost Structure
    Figure 51. Channels of Distribution (Direct Sales, and Distribution)
    Figure 52. Bottom-up and Top-down Approaches for This Report
    Figure 53. Data Triangulation

Description

Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

The global market for Sickle-cell Anemia Therapeutics was estimated to be worth US$ 1845.9 million in 2023 and is forecast to a readjusted size of US$ 5067.2 million by 2030 with a CAGR of 15.0% during the forecast period 2024-2030

Market Segmentation